Shire PLC and its subsidiaries will pay $350m to settle state and federal allegations the manufacturer paid kickbacks and used other illegal means to encourage providers to use its Dermagraft human skin substitute. The product was FDA-approved to treat diabetic foot ulcers.
This is the largest civil settlement to date in a device-related False Claims Act case, the Department of Justice said in announcing the Jan. 11 agreement.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?